Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

NORTHERN NEW ENGLAND DIAGNOSTICS

NPI: 1013205558 · MANCHESTER, ME 04351 · Clinical Medical Laboratory · NPI assigned 07/19/2011

$96K
Total Medicaid Paid
6,346
Total Claims
4,756
Beneficiaries
14
Codes Billed
2018-01
First Month
2019-07
Last Month

Provider Details

Authorized OfficialMRAZIK, MADELINE (BUSINESS MANAGER)
NPI Enumeration Date07/19/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,756 $69K
2019 1,590 $27K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,159 1,564 $39K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 869 548 $35K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 618 469 $18K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 70 59 $2K
80053 Comprehensive metabolic panel 589 475 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 497 389 $864.52
36415 Collection of venous blood by venipuncture 605 490 $356.76
84443 Thyroid stimulating hormone (TSH) 53 42 $270.72
84439 88 54 $117.86
99001 78 77 $0.00
80364 187 175 $0.00
80361 27 25 $0.00
99000 420 306 $0.00
80349 86 83 $0.00